Trial Profile
Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients With Iron Deficiency Anemia and Impaired Renal Function
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary) ; Iron sucrose
- Indications Iron deficiency anaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms REPAIR-IDA
- Sponsors American Regent; Luitpold Pharmaceuticals
- 26 Jun 2014 New trial record